Compare LBRT & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LBRT | TGTX |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.9B |
| IPO Year | 2017 | 2008 |
| Metric | LBRT | TGTX |
|---|---|---|
| Price | $28.22 | $28.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | $23.00 | ★ $50.67 |
| AVG Volume (30 Days) | ★ 4.6M | 1.5M |
| Earning Date | 04-30-2026 | 05-29-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | 0.89 | ★ 2.77 |
| Revenue | ★ $4,006,116,000.00 | $2,785,000.00 |
| Revenue This Year | $0.02 | $90.97 |
| Revenue Next Year | $8.06 | $45.74 |
| P/E Ratio | $31.26 | ★ $10.42 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.50 | $25.37 |
| 52 Week High | $28.95 | $46.48 |
| Indicator | LBRT | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 67.44 | 44.34 |
| Support Level | $10.82 | $27.25 |
| Resistance Level | N/A | $33.05 |
| Average True Range (ATR) | 1.26 | 1.12 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 89.24 | 25.79 |
Liberty Energy Inc is a integrated energy services and technology company focused on providing hydraulic fracturing services and related technologies to onshore oil and natural gas exploration and production (E&P) companies. The Company offers customers with hydraulic fracturing services, together with complementary services including wireline services, proppant delivery solutions, field gas processing and treating, compressed natural gas (CNG) delivery, data analytics, related goods (including sand mine operations), and technologies to facilitate lower emission completions, thereby helping customers reduce emissions profile. The company provides services across USA and Canada.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.